Personalization of mAb therapies based on a genomic and bioinformatic study

GenomAbs offers a precise preventive personalization of monoclonal antibody therapies. A genomic study of each patient will be performed to evaluate their genetic predispositions to the success or failure of each therapy.


Laura Beltrán, CMO, MSc. student in Business Administration and Bioentrepreneurship, CBS.

Cristina Abascal, CEO, PhD student in Bioengineering, UCD.

Irene Martínez, CTO, MSc. student in Bioinformatics and Biostatistics, UOC and UB.


Health Innovators 2022